Brooklyn, NY – Shiel Medical Laboratory is the only clinical laboratory worldwide to offer the Oxidized LDL Triple Marker Test. It is the only blood test available that measures atherosclerotic disease activity in the artery wall.

The Shiel Oxidized LDL Triple Marker Test combines and integrates Three Pathophysiological Components of the Atherosclerotic Disease Process with Three Corresponding Independent Biomarkers into One Natural Logarithmic Equation, Yielding One Numerical Result with One Well-Defined Coronary Artery Disease Risk Level.

Oxidized LDL – Oxidized LDL is the atherogenic form of LDL. Oxidized LDL is a plaque-specific lipoprotein which plays a key role in the atherosclerotic disease process, particularly in the deposition of cholesterol in the artery wall plaque. Oxidized LDL is found primarily in the atherosclerotic plaque and NOT in normal arteries. Oxidized LDL is directly involved in the initiation and progression of atherosclerosis: from the early-stage conversion of monocyte/macrophages into cholesterol-laden foam cells, to the late-stage development of plaque instability and rupture.

hs-CRP is an independent, non-specific biomarker of inflammation and tissue injury. Chronically elevated levels of hs-CRP are associated with high cardiovascular disease (CVD) risk, whereas persistently low hs-CRP levels are associated with low CVD risk and even longevity. Very high (acute) hs-CRP levels (greater than 7.0 mg/L) are associated with infection and acute inflammation, arthritis, lupus, and other non-cardiovascular diseases. Shiel Medical Laboratory will not calculate Triple Marker Test results when the hs-CRP results are greater than 7.0 mg/L, consistent with acute inflammation.

HDL – High-density-lipoprotein inhibits the pathophysiological action of Oxidized LDL. In this regard, HDL should be viewed as an Oxidized LDL antagonist. HDL is also involved in the removal (reverse transport) of cholesterol from the artery walls to the blood stream, and then to the liver where cholesterol is converted to bile acids and then excreted in the bile. High HDL cholesterol levels (above 60 mg/dL) are anti-atherogenic and atheroprotective, and are associated with low risk of coronary artery disease. In contrast, low HDL cholesterol levels (less than 40 mg/dL) are associated with a high risk of coronary artery disease.

Key Features of the Oxidized LDL Triple Marker Test

•  Clinically Proven, Innovative Cardiovascular Disease Risk Assessment Test
•  Potential Replacement for All Current Blood Lipid Tests, including Total Cholesterol and LDL-Cholesterol.
•  Reflects Atherosclerotic Disease Activity in the Artery Wall.

Contact Tod Schild at ts@shiel.com or 516-314-3873 for more information, or to obtain reprints of studies published in the American Journal of Cardiology, JAMA, and the New England Journal of Medicine.

View OXLDL Triple Marker Test Brochure